在线自适应放疗:规划技术评估及其对胰腺癌纵向计划质量稳健性的影响
研究纳入67例不可手术胰腺癌患者,接受50 Gy/5次立体定向磁共振引导自适应放疗(SMART)。评估靶区覆盖、均匀性、适形性及新开发的胰腺自适应放疗评分(PARTS),发现自适应计划与基线计划质量相似,在GI PRV技术和环引导下稳健且稳定。
要点
- 基线计划与自适应计划均满足OAR约束(基线n=67,自适应n=318)。
- 自适应计划靶区覆盖较基线略低:PTV D80% 44.3±5.5 Gy vs 44.9±5.8 Gy。
- 稳定性除PARTS外无统计学差异(p>0.05);PARTS p=0.04,中位差异-0.6%。
核心结论
- 描述了一种5次消融性SMART规划方法,在在线自适应过程中稳健且稳定,得益于GI PRV技术控制的梯度和环的使用。
- 这些发现值得注意,因为每日分次间GI OAR解剖差异是常规的,因此需要在线自适应。
- 这项工作支持利用患者无关的模板在线自适应方法的可行性。
研究设计与样本
- 研究纳入67例不可手术胰腺癌患者,处方50 Gy/5次SMART。
- 基线规划包括3-5 mm胃肠道(GI)PRV、基于GI PRV的50 Gy优化靶区(PTVopt)、适形环和收缩GTV以引导热点。
- 每次自适应时重新勾画GI解剖,随后重新优化。
- 评估计划质量指标包括靶区覆盖(TC=PTVopt V100%/体积)、PTV D90%和D80%、均匀性指数(HI=PTVopt D2%/D98%)、处方等剂量/靶体积(PITV)、低剂量适形性(D2cm=距PTVopt 2 cm处最大剂量/Rx剂量)和梯度指数(R50%=50% Rx等剂量体积/PTVopt体积)。
- 开发并实施了一种新的全局规划指标,称为胰腺自适应放疗评分(PARTS),基于GI OAR保护、PTV/GTV覆盖和适形性。
主要发现
- OAR约束在所有基线(n=67)和自适应(n=318)计划中均满足。
- 基线/自适应计划的覆盖率为均值±SD:PTV D80% 44.9±5.8 Gy/44.3±5.5 Gy,PTVopt D80% 50.1±4.2 Gy/49.1±4.7 Gy,TC 80%±18%/74%±18%。
- 基线/自适应计划的均匀性和适形性为:PITV 0.87±0.25/0.81±0.30,R50% 3.81±1.87/3.87±2.0,HI 1.53±0.23/1.55±0.23,D2cm 58%±7%/59%±7%。
- PARTS被发现是一个敏感指标,因为几何变化对其子指标具有累加影响。
- 稳定性方面除PARTS外无统计学差异(p>0.05),PARTS p=0.04,中位差异-0.6%。
关键数值与推荐
- 基线规划包括3-5 mm胃肠道(GI)PRV、50 Gy优化靶区(PTVopt)基于GI PRV、适形环和收缩GTV以引导热点。
- 处方剂量为50 Gy/5次。
- OAR约束在所有基线(n=67)和自适应(n=318)计划中均满足。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: Planning on a static dataset that reflects the simulation day anatomy is routine for SBRT. We hypothesize the quality of on-table adaptive plans is similar to the baseline plan when delivering stereotactic MR-guided adaptive radiotherapy (SMART) for pancreatic cancer (PCa). MATERIALS AND METHODS: Sixty-seven inoperable PCa patients were prescribed 50 Gy/5-fraction SMART. Baseline planning included: 3-5 mm gastrointestinal (GI) PRV, 50 Gy optimization target (PTVopt) based on GI PRV, conformality rings, and contracted GTV to guide the hotspot. For each adaptation, GI anatomy was re-contoured, followed by re-optimization. Plan quality was evaluated for target coverage (TC = PTVopt V100%/volume), PTV D90% and D80%, homogeneity index (HI = PTVopt D2%/D98%), prescription isodose/target volume (PITV), low-dose conformity (D2cm = maximum dose at 2 cm from PTVopt/Rx dose), and gradient index (R50%=50% Rx isodose volume/PTVopt volume).A novel global planning metric, termed the Pancreas Adaptive Radiotherapy Score (PARTS), was developed and implemented based on GI OAR sparing, PTV/GTV coverage, and conformality. Adaptive robustness (baseline to fraction 1) and stability (difference between two fractions with highest GI PRV variation) were quantified. RESULTS: OAR constraints were met on all baseline (n = 67) and adaptive (n = 318) plans. Coverage for baseline/adaptive plans was mean ± SD at 44.9 ± 5.8 Gy/44.3 ± 5.5 Gy (PTV D80%), 50.1 ± 4.2 Gy/49.1 ± 4.7 Gy (PTVopt D80%), and 80%±18%/74%±18% (TC), respectively. Mean homogeneity and conformality for baseline/adaptive plans were 0.87 ± 0.25/0.81 ± 0.30 (PITV), 3.81 ± 1.87/3.87 ± 2.0 (R50%), 1.53 ± 0.23/1.55 ± 0.23 (HI), and 58%±7%/59%±7% (D2cm), respectively. PARTS was found to be a sensitive metric due to its additive influence of geometry changes on PARTS' sub-metrics. There were no statistical differences (p > 0.05) for stability, except for PARTS (p = 0.04, median difference -0.6%). Statistical differences for robustness when significant were small for most metrics (<2.0% median). Median adaptive re-optimizations were 2. CONCLUSION: We describe a 5-fraction ablative SMART planning approach for PCa that is robust and stable during on-table adaption, due to gradients controlled by a GI PRV technique and the use of rings. These findings are noteworthy given that daily interfraction anatomic GI OAR differences are routine, thus necessitating on-table adaptation. This work supports feasibility towards utilizing a patient-independent, template on-table adaptive approach.
引用
- Mittauer KE, Yarlagadda S, Bryant JM, et al. Online adaptive radiotherapy: Assessment of planning technique and its impact on longitudinal plan quality robustness in pancreatic cancer. Radiother Oncol. 2023. PMID: 37657726. doi:10.1016/j.radonc.2023.109869
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。